Debora Barton News Today

Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial developmentWALTHAM, Mass., April 08, 2024 -- TScan Therapeutics, Inc. , a clinical-stage...

TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing...

WALTHAM, Mass., Feb. 06, 2024 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment...

Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies

TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapyWALTHAM, Mass., Aug. 29, 2023 -- TScan...

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic test with TScan Therapeutics, a clinical-stage...

Cook County expanding suburban urgent care, a staffing firm is paying back a pay settlement and more in today's Health Pulse.

TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on... | June 6, 2023

10.08.2022 - Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings ...

/PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies,...